Unichem recently launched Ivazine, a novel anti-anginal to cater to unmet needs in angina therapy. Ivazine is an effective and relatively safer anti-anginal. It acts by selectively reducing the heart rate to the desired level, which is why it doesn’t have the side-effects shown by other anti-anginals.
Ivabradine is recommended for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta–blockers.
Ivazine is available in two strengths containing Ivabradine in 5 mg and 7.5 mg doses. Each strength is available in pack of 10 tablets.